Oyster Extract "News" for your good health!
Current News which
discusses available
Blood and Immune products.
CURRENT NEWS-February 16, 2005
News Articles of Interest, related to the usage of Oyster Extract Health Supplements.
The Immune System is your natural ability to protect your body from disease. Zinc activates the correct function of your immune cells. Studies show that people who suffer from Zinc deficiency nearly always have a decreased immune system and are subject to infections and illness.
Each month, OY-EX.com will provide an interesting article of topical discussion regarding medical issues related to liver disease. OY-EX is an important part of a regime to maintain good health, including the best vitamins and minerals found in nature to provide a healthy liver and immune system.
Research
Bioenvision Evaluates New Agent in Fight against Hepatitis C
Patient Enrollment Begins in Multi-Center, International Phase II Clinical Trial
NEW YORK--(BUSINESS WIRE)
Feb. 16, 2005
Bioenvision, Inc. (Nasdaq:BIVN) today announced that the first patients has been enrolled in a multi-center, international Phase II clinical trial to evaluate the clinical efficacy of Virostat for the treatment of chronic hepatitis C.
The investigator sponsored trial is being conducted at specialist centers in Europe and Egypt and will assess the ability of Virostat to reduce viral load and improve quality of life in patients with chronic hepatitis C.
"This begins a new phase of development for Bioenvision, and we look forward to the opportunity to build value in our non-cancer related franchises," said Dr. Chris Wood, Chairman and CEO of Bioenvision. He added, "Current therapies for hepatitis C are costly and not always effective. We hope to offer an alternative in the fight against this epidemic."
About Hepatitis C
Hepatitis C is a viral infection of the liver. The virus, HCV, is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. HCV is spread primarily by direct contact with human blood. The major causes of HCV infection worldwide are use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized. The World Health Organization has declared hepatitis C a global health problem, with approximately 3% of the world's population infected with HCV and it varies considerably by region. The prevalence in the US is estimated at 1.3% or approximately 3.5 million people. Egypt has a population of approximately 62 million and contains the highest prevalence of hepatitis C in the world, estimated at over 20% of the nation's approximately 62 million people.
About Virostat
Virostat has shown potent viricidal activity in vitro,. Virostat is an effective against viruses such as HIV and West Nile Virus in laboratory tests. Bioenvision obtained global license rights from Oklahoma Medical Research Foundation (OMRF) for the right to develop and market Virostat for anti-viral indications.
About Bioenvision
Bioenvision's (Nasdaq:BIVN - News) primary focus is the acquisition, development and distribution of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: clofarabine (in co-development with Genzyme Corporation), Modrenal(R) (for which Bioenvision has obtained regulatory approval for marketing in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy), and other products in clinical trials. Bioenvision is also developing anti-infective technologies, including the Oligon technology; an advanced biomaterial that has been incorporated into various FDA approved medical devices. For more information on Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Bioenvision's compounds under development in particular; the potential failure of Bioenvision's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioenvision's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioenvision's business, structure or projections; the development of competing products; uncertainties related to Bioenvision's dependence on third parties and partners; and those risks described in Bioenvision's filings with the SEC. Bioenvision disclaims any obligation to update these forward-looking statements.
CURRENT NEWS-February 24, 2005
